ES2721031T3 - Compuestos de dihidroisoquinolinona sustituidos - Google Patents
Compuestos de dihidroisoquinolinona sustituidos Download PDFInfo
- Publication number
- ES2721031T3 ES2721031T3 ES15730290T ES15730290T ES2721031T3 ES 2721031 T3 ES2721031 T3 ES 2721031T3 ES 15730290 T ES15730290 T ES 15730290T ES 15730290 T ES15730290 T ES 15730290T ES 2721031 T3 ES2721031 T3 ES 2721031T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- cycloalkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un compuesto de formula (I):**Fórmula** o una sal farmacéuticamente aceptable del mismo, en la que: R1 se selecciona del grupo que consiste en F, alquilo C1-C4, alcoxi C1-C4, C(O)R5, cicloalquilo C3-C8, heterociclilo de 3-12 miembros y heteroarilo de 5-12 miembros, en la que cada alquilo C1-C4 o alcoxi C1-C4 está opcionalmente sustituido con uno o más R6, y cada uno de dichos cicloalquilo C3-C8, heterociclilo de 3-12 miembros o heteroarilo de 5-12 miembros está opcionalmente sustituido con uno o más R7; R2 es H, F o alquilo C1-C4; L es un enlace o un alquileno C1-C4; R3 se selecciona del grupo que consiste en alquilo C1-C4, alcoxi C1-C4, OH, CN, C(O)R8, COOR9, NR10R11, OR12, cicloalquilo C3-C8, heterociclilo de 3-12 miembros y heteroarilo de 5-12 miembros, en la que cada uno de dichos alquilo C1-C4 o alcoxi C1-C4 está opcionalmente sustituido con uno o más R6, y cada uno de dichos cicloalquilo C3-C8, heterociclilo de 3-12 miembros o heteroarilo de 5-12 miembros está opcionalmente sustituido con uno o más R7; R4 es H, halo o alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R6; R5 es alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; cada R6 es independientemente OH, F, CN o alcoxi C1-C4; cada R7 es independientemente alquilo C1-C4, OH, F, CN, alcoxi C1-C4, =O, o C(O)R13; R8 es alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; R9 es H o alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; R10 y R11 son independientemente H o alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R14; R12 se selecciona del grupo que consiste en cicloalquilo C3-C8, heterociclilo de 3-12 miembros y heteroarilo de 5-12 miembros, en la que cada uno de dichos cicloalquilo C3-C8, heterociclilo de 3-12 miembros o heteroarilo de 5-12 miembros está opcionalmente sustituido con uno o más R7; cada R13 es independientemente alquilo C1-C4, en la que cada alquilo C1-C4 está opcionalmente sustituido con uno o más R15; cada R14 y R15 es independientemente OH, F, CN o alcoxi C1-C4; y X y Z son independientemente alquilo C1-C4, fluoroalquilo C1-C4, alcoxi C1-C4 o fluoroalcoxi C1-C4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013410P | 2014-06-17 | 2014-06-17 | |
US201562156533P | 2015-05-04 | 2015-05-04 | |
PCT/IB2015/054272 WO2015193765A1 (en) | 2014-06-17 | 2015-06-05 | Substituted dihydroisoquinolinone compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2721031T3 true ES2721031T3 (es) | 2019-07-26 |
Family
ID=53434412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES15730290T Active ES2721031T3 (es) | 2014-06-17 | 2015-06-05 | Compuestos de dihidroisoquinolinona sustituidos |
Country Status (40)
Country | Link |
---|---|
US (4) | US9481666B2 (es) |
EP (2) | EP3157915B1 (es) |
JP (1) | JP6152495B1 (es) |
KR (1) | KR101877187B1 (es) |
CN (1) | CN107207464B (es) |
AP (1) | AP2016009605A0 (es) |
AU (1) | AU2015275826B2 (es) |
BR (1) | BR112016029612B1 (es) |
CA (1) | CA2894298C (es) |
CL (1) | CL2016003246A1 (es) |
CR (2) | CR20160574A (es) |
CU (1) | CU24408B1 (es) |
CY (1) | CY1121706T1 (es) |
DK (1) | DK3157915T3 (es) |
EA (1) | EA031892B1 (es) |
ES (1) | ES2721031T3 (es) |
GE (1) | GEP20186933B (es) |
HR (1) | HRP20190604T1 (es) |
HU (1) | HUE042964T2 (es) |
IL (1) | IL248991B (es) |
LT (1) | LT3157915T (es) |
MA (1) | MA40225B1 (es) |
MD (1) | MD4820C1 (es) |
ME (1) | ME03419B (es) |
MX (1) | MX2016016764A (es) |
MY (1) | MY185765A (es) |
NZ (1) | NZ726108A (es) |
PE (1) | PE20161552A1 (es) |
PH (1) | PH12016502378A1 (es) |
PL (1) | PL3157915T3 (es) |
PT (1) | PT3157915T (es) |
RS (1) | RS58632B1 (es) |
SG (1) | SG11201609386YA (es) |
SI (1) | SI3157915T1 (es) |
SV (1) | SV2016005333A (es) |
TN (1) | TN2016000529A1 (es) |
TW (1) | TWI561516B (es) |
UA (1) | UA118380C2 (es) |
UY (1) | UY36170A (es) |
WO (1) | WO2015193765A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
EA031892B1 (ru) | 2014-06-17 | 2019-03-29 | Пфайзер Инк. | Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2 |
TW201708210A (zh) * | 2015-06-30 | 2017-03-01 | 葛蘭素史克智慧財產(第二)有限公司 | Zeste同源物2增強子之抑制劑 |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
CA3023157A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
EP3655392A1 (en) | 2017-07-17 | 2020-05-27 | Abbvie Deutschland GmbH & Co. KG | 1,2,3,4-substituted quinoline compounds as s1p modulators |
SG11202003477QA (en) * | 2017-11-14 | 2020-05-28 | Pfizer | Ezh2 inhibitor combination therapies |
MX2020007974A (es) | 2018-01-31 | 2020-09-07 | Mirati Therapeutics Inc | Inhibidores de complejo represivo polycomb 2 (prc2). |
CN111989325A (zh) | 2018-04-18 | 2020-11-24 | 星座制药公司 | 甲基修饰酶的调节剂、其组合物和用途 |
WO2019226491A1 (en) * | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN112399857A (zh) | 2018-07-09 | 2021-02-23 | 盲人庇护基金会 | Prc2亚单位的抑制治疗眼失调 |
WO2020086857A1 (en) * | 2018-10-24 | 2020-04-30 | Vanderbilt University | Wdr5 inhibitors and modulators |
KR20200101219A (ko) * | 2019-02-19 | 2020-08-27 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
WO2022018594A1 (en) | 2020-07-20 | 2022-01-27 | Pfizer Inc. | Synthesis of novel intermediates for substituted 3,4-dihydroisoquinolinones |
CA3165787C (en) * | 2020-08-13 | 2023-06-06 | Seung Hyun Jung | Novel dioxoloisoquinolinone derivatives and use thereof |
US20240101535A1 (en) * | 2020-12-11 | 2024-03-28 | Etern Biopharma (Shanghai) Co., Ltd. | Dihydroisoquinolinone derivative and application thereof |
WO2023098880A1 (zh) * | 2021-12-02 | 2023-06-08 | 上海翰森生物医药科技有限公司 | 稠环类衍生物调节剂、其制备方法和应用 |
WO2023111810A1 (en) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Combination therapies and uses for treating cancer |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3846412A (en) | 1971-03-18 | 1974-11-05 | Lepetit Spa | Dihydro-2-amino-isoquinolines and their derivatives |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
WO2000035296A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Improved release of medicament active agents from a chewing gum coating |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
US20070093515A1 (en) | 2005-08-16 | 2007-04-26 | Arrington Mark P | Phosphodiesterase 10 inhibitors |
CA2631777A1 (en) * | 2005-12-22 | 2007-07-05 | Wyeth | Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor |
US20100113415A1 (en) | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
AU2009261764B2 (en) * | 2008-06-17 | 2013-01-10 | Astrazeneca Ab | Pyridine compounds |
US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
US20110251216A1 (en) | 2010-02-19 | 2011-10-13 | The Regents Of The University Of Michigan | Compositions and methods for inhibiting ezh2 |
JP5889875B2 (ja) | 2010-05-07 | 2016-03-22 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | アザインダゾール |
WO2011140324A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indoles |
WO2011140325A1 (en) | 2010-05-07 | 2011-11-10 | Glaxosmithkline Llc | Indazoles |
PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
WO2012068589A2 (en) | 2010-11-19 | 2012-05-24 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
TWI598336B (zh) * | 2011-04-13 | 2017-09-11 | 雅酶股份有限公司 | 經取代之苯化合物 |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
BR112014007603A2 (pt) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | métodos de tratamento do câncer |
WO2013059944A1 (en) * | 2011-10-28 | 2013-05-02 | British Columbia Cancer Agency Branch | Epigenetic regulators and uses thereof |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
JP6254169B2 (ja) | 2012-09-28 | 2017-12-27 | ファイザー・インク | ベンズアミドおよびヘテロベンズアミド化合物 |
LT2935303T (lt) | 2012-12-21 | 2021-03-25 | Janssen Biopharma, Inc. | 4'-fluor-nukleozidai, 4'-fluor-nukleotidai ir jų analogai, skirti hcv gydymui |
CN111303152B (zh) | 2012-12-21 | 2023-04-11 | 吉利德科学公司 | 多环-氨基甲酰基吡啶酮化合物及其药物用途 |
US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
FR3000065A1 (fr) | 2012-12-21 | 2014-06-27 | Univ Lille Ii Droit & Sante | Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes |
KR20150096433A (ko) | 2012-12-21 | 2015-08-24 | 사노피 | 이중 glp1/gip 또는 삼중 glp1/gip/글루카곤 효능제 |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
UY35240A (es) | 2012-12-21 | 2014-07-31 | Plexxikon Inc | Compuestos y métodos para la modulación de quinasas y sus indicaciones |
FR3000059A1 (fr) | 2012-12-21 | 2014-06-27 | Saint Gobain Placo | Composition pour plaques de platre et produits obtenus |
HUE039848T2 (hu) | 2012-12-21 | 2019-02-28 | Hoffmann La Roche | Peptidek oxitocin agonistákként |
JP6678455B2 (ja) | 2012-12-21 | 2020-04-08 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
EA031892B1 (ru) | 2014-06-17 | 2019-03-29 | Пфайзер Инк. | Замещенные дигидроизохинолиноновые соединения для лечения аномального клеточного роста, ассоциированного с активностью ezh2 |
-
2015
- 2015-06-05 EA EA201692114A patent/EA031892B1/ru unknown
- 2015-06-05 MA MA40225A patent/MA40225B1/fr unknown
- 2015-06-05 ME MEP-2019-85A patent/ME03419B/me unknown
- 2015-06-05 EP EP15730290.2A patent/EP3157915B1/en active Active
- 2015-06-05 NZ NZ726108A patent/NZ726108A/en unknown
- 2015-06-05 CU CU2016000180A patent/CU24408B1/es unknown
- 2015-06-05 CR CR20160574A patent/CR20160574A/es unknown
- 2015-06-05 RS RS20190512A patent/RS58632B1/sr unknown
- 2015-06-05 MY MYPI2016704453A patent/MY185765A/en unknown
- 2015-06-05 LT LTEP15730290.2T patent/LT3157915T/lt unknown
- 2015-06-05 CR CR20200484A patent/CR20200484A/es unknown
- 2015-06-05 UA UAA201611695A patent/UA118380C2/uk unknown
- 2015-06-05 TN TN2016000529A patent/TN2016000529A1/en unknown
- 2015-06-05 GE GEAP201514347A patent/GEP20186933B/en unknown
- 2015-06-05 AU AU2015275826A patent/AU2015275826B2/en active Active
- 2015-06-05 PL PL15730290T patent/PL3157915T3/pl unknown
- 2015-06-05 BR BR112016029612-5A patent/BR112016029612B1/pt active IP Right Grant
- 2015-06-05 EP EP19159058.7A patent/EP3521285A1/en not_active Withdrawn
- 2015-06-05 PT PT15730290T patent/PT3157915T/pt unknown
- 2015-06-05 AP AP2016009605A patent/AP2016009605A0/en unknown
- 2015-06-05 SG SG11201609386YA patent/SG11201609386YA/en unknown
- 2015-06-05 CN CN201580032058.7A patent/CN107207464B/zh active Active
- 2015-06-05 SI SI201530698T patent/SI3157915T1/sl unknown
- 2015-06-05 PE PE2016002737A patent/PE20161552A1/es unknown
- 2015-06-05 MX MX2016016764A patent/MX2016016764A/es active IP Right Grant
- 2015-06-05 ES ES15730290T patent/ES2721031T3/es active Active
- 2015-06-05 MD MDA20160136A patent/MD4820C1/ro active IP Right Grant
- 2015-06-05 HU HUE15730290A patent/HUE042964T2/hu unknown
- 2015-06-05 WO PCT/IB2015/054272 patent/WO2015193765A1/en active Application Filing
- 2015-06-05 KR KR1020177001230A patent/KR101877187B1/ko active IP Right Grant
- 2015-06-05 JP JP2016573051A patent/JP6152495B1/ja active Active
- 2015-06-05 DK DK15730290.2T patent/DK3157915T3/en active
- 2015-06-15 TW TW104119287A patent/TWI561516B/zh active
- 2015-06-16 CA CA2894298A patent/CA2894298C/en active Active
- 2015-06-16 US US14/740,439 patent/US9481666B2/en active Active
- 2015-06-16 UY UY0001036170A patent/UY36170A/es not_active Application Discontinuation
-
2016
- 2016-09-12 US US15/262,230 patent/US20160376254A1/en not_active Abandoned
- 2016-11-15 IL IL248991A patent/IL248991B/en active IP Right Grant
- 2016-11-29 PH PH12016502378A patent/PH12016502378A1/en unknown
- 2016-12-05 SV SV2016005333A patent/SV2016005333A/es unknown
- 2016-12-19 CL CL2016003246A patent/CL2016003246A1/es unknown
-
2017
- 2017-06-28 US US15/635,648 patent/US20170298048A1/en not_active Abandoned
-
2018
- 2018-10-10 US US16/156,304 patent/US10570121B2/en active Active
-
2019
- 2019-03-28 HR HRP20190604TT patent/HRP20190604T1/hr unknown
- 2019-04-05 CY CY20191100381T patent/CY1121706T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2721031T3 (es) | Compuestos de dihidroisoquinolinona sustituidos | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
CR20170066A (es) | Compuestos aminopirimidinilo como inhibidires de jak | |
AR101558A1 (es) | Difluoropirrolidinas como moduladores del receptor de orexina | |
AR110405A1 (es) | Compuestos | |
AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
AR099677A1 (es) | Compuesto heterocíclico fusionado y su uso para el control de plagas | |
AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
CO2017001178A2 (es) | Derivado de piridona que tiene un grupo tetrahidropiranil metilo | |
AR097866A1 (es) | Derivados de 4-azaindol | |
AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
AR094762A1 (es) | Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo | |
CO2018003367A2 (es) | Benzamidas sustituidas con isoxazolina y análogos como insecticidas | |
AR091519A1 (es) | Inhibidores pirrolopirazona de tanquirasa | |
AR095421A1 (es) | Moduladores de p2x7 | |
MY178370A (en) | Aqueous composition | |
AR099071A1 (es) | Antagonistas selectivos de nr2b | |
AR104539A1 (es) | Compuestos cíclicos | |
PH12018500668A1 (en) | Therapeutic compounds and methods of use thereof | |
AR081349A1 (es) | Carboxamidas de pirazinilo como fungicidas | |
AR093827A1 (es) | Agentes antibacterianos de tetrahidroquinolina triciclica | |
AR096161A1 (es) | Derivados de triazina | |
AR123241A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
AR103728A1 (es) | Dimetoxifenilos como inhibidores del transportador de monoamina vesicular 2 |